WO2009055076A3 - Methods and compositions for inhibition of immune responses and autoimmunity - Google Patents

Methods and compositions for inhibition of immune responses and autoimmunity Download PDF

Info

Publication number
WO2009055076A3
WO2009055076A3 PCT/US2008/012220 US2008012220W WO2009055076A3 WO 2009055076 A3 WO2009055076 A3 WO 2009055076A3 US 2008012220 W US2008012220 W US 2008012220W WO 2009055076 A3 WO2009055076 A3 WO 2009055076A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunoregulatory
autoimmunity
inhibition
compositions
methods
Prior art date
Application number
PCT/US2008/012220
Other languages
French (fr)
Other versions
WO2009055076A2 (en
Inventor
Franck Barrat
Robert L. Coffman
Tracy Matray
Cristiana Guiducci
Original Assignee
Dynavax Technologies Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Technologies Corporation filed Critical Dynavax Technologies Corporation
Priority to AU2008317261A priority Critical patent/AU2008317261B2/en
Priority to CA2703931A priority patent/CA2703931C/en
Priority to EP08841867.8A priority patent/EP2209896B1/en
Priority to JP2010531068A priority patent/JP5749492B2/en
Publication of WO2009055076A2 publication Critical patent/WO2009055076A2/en
Publication of WO2009055076A3 publication Critical patent/WO2009055076A3/en
Priority to US12/767,692 priority patent/US8962579B2/en
Priority to US14/613,280 priority patent/US9476053B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/331—Universal or degenerate base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications

Abstract

The application relates to the use of immunoregulatory polynucleotides and/or immunoregulatory compounds in combination with other therapeutic agents. The application further relates to immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence. It also relates to the administration of the immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence to regulate an immune response.
PCT/US2008/012220 2007-10-26 2008-10-27 Methods and compositions for inhibition of immune responses and autoimmunity WO2009055076A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2008317261A AU2008317261B2 (en) 2007-10-26 2008-10-27 Methods and compositions for inhibition of immune responses and autoimmunity
CA2703931A CA2703931C (en) 2007-10-26 2008-10-27 Methods and compositions for inhibition of immune responses and autoimmunity
EP08841867.8A EP2209896B1 (en) 2007-10-26 2008-10-27 Methods and compositions for inhibition of immune responses and autoimmunity
JP2010531068A JP5749492B2 (en) 2007-10-26 2008-10-27 Methods and compositions for inhibiting immune responses and autoimmunity
US12/767,692 US8962579B2 (en) 2007-10-26 2010-04-26 Methods and compositions for inhibition of immune responses and autoimmunity
US14/613,280 US9476053B2 (en) 2007-10-26 2015-02-03 Methods and compositions for inhibition of immune responses and autoimmunity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98307307P 2007-10-26 2007-10-26
US60/983,073 2007-10-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/767,692 Continuation US8962579B2 (en) 2007-10-26 2010-04-26 Methods and compositions for inhibition of immune responses and autoimmunity

Publications (2)

Publication Number Publication Date
WO2009055076A2 WO2009055076A2 (en) 2009-04-30
WO2009055076A3 true WO2009055076A3 (en) 2009-11-05

Family

ID=40513681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/012220 WO2009055076A2 (en) 2007-10-26 2008-10-27 Methods and compositions for inhibition of immune responses and autoimmunity

Country Status (6)

Country Link
US (2) US8962579B2 (en)
EP (2) EP2209896B1 (en)
JP (1) JP5749492B2 (en)
AU (1) AU2008317261B2 (en)
CA (1) CA2703931C (en)
WO (1) WO2009055076A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385657T3 (en) 2004-09-01 2012-07-27 Dynavax Technologies Corporation Methods and compositions for the inhibition of innate immune responses and autoimmunity
AU2005316503A1 (en) * 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
ES2542989T3 (en) 2005-10-12 2015-08-13 Idera Pharmaceuticals, Inc. Immuno-regulatory oligonucleotide compounds (IRO) to modulate the Toll-like receptor-based immune response
AU2008317261B2 (en) 2007-10-26 2015-04-09 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
AU2009302468A1 (en) * 2008-10-06 2010-04-15 Idera Pharmaceuticals, Inc. Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
WO2011159328A1 (en) * 2010-06-16 2011-12-22 Dynavax Technologies Corporation Methods of treatment using tlr7 and/or tlr9 inhibitors
CN103153346A (en) * 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 Methods of treatment using tlr7 and/or tlr9 inhibitors
CA2817891C (en) 2010-11-19 2021-10-12 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
US9868955B2 (en) 2012-09-29 2018-01-16 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
CN105597079A (en) * 2016-01-11 2016-05-25 中国人民解放军第三军医大学第一附属医院 Medicine for treating psoriasis
CN105541947A (en) * 2016-01-11 2016-05-04 中国人民解放军第三军医大学第一附属医院 Drug molecule for antagonizing TLR7/8 and TLR9 activation and application
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
WO2017214378A1 (en) 2016-06-08 2017-12-14 President And Fellows Of Harvard College Engineered viral vector reduces induction of inflammatory and immune responses
MX2022001870A (en) 2019-08-14 2022-05-30 Curevac Ag Head-up display.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
WO2001068697A2 (en) * 2000-03-17 2001-09-20 Gorczynski Reginald M Methods and compositions for immunoregulation
WO2003085110A2 (en) * 2002-04-05 2003-10-16 Santaris Pharma A/S Oligomeric compounds for the modulation hif-1alpha expression
WO2005086835A2 (en) * 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
WO2007095387A2 (en) * 2006-02-17 2007-08-23 Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US983073A (en) 1908-05-28 1911-01-31 Arcade Mallet Kinematographic apparatus.
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4849513A (en) 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5015733A (en) 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US4910300A (en) 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US6312679B1 (en) 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US5338532A (en) 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
JP3012244B2 (en) 1987-09-21 2000-02-21 ジェン―プローブ インコーポレイテッド Non-nucleotide ligation reagent for nucleotide probes
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US6096722A (en) * 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
DK0748382T3 (en) 1993-09-02 2003-02-17 Ribozyme Pharm Inc Enzymatic nucleic acid containing non-nucleotide
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
JP2000512981A (en) 1996-06-06 2000-10-03 ラ ホヤ ファーマシューティカル カンパニー aPL immunoreactive peptide, conjugate thereof and method of treatment for aPL antibody-mediated pathology
ES2241042T3 (en) 1996-10-11 2005-10-16 The Regents Of The University Of California IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA.
WO2002090526A2 (en) 2001-03-21 2002-11-14 Human Genome Sciences, Inc. Human secreted proteins
US6489304B2 (en) * 1997-05-01 2002-12-03 Hybridon, Inc. Hyperstructure-forming carriers
EP2085090A3 (en) 1997-06-06 2012-05-02 The Regents of the University of California Inhibitors of DNA immunostimulatory sequence activity
US6080580A (en) * 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
AU4343700A (en) 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
EP1183230A1 (en) 1999-06-08 2002-03-06 La Jolla Pharmaceutical Valency platform molecules comprising aminooxy groups
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
WO2002010438A2 (en) 2000-07-28 2002-02-07 The Johns Hopkins University Serial analysis of transcript expression using long tags
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
SE0201701D0 (en) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2004014322A2 (en) 2002-08-12 2004-02-19 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
CN101955976A (en) 2002-11-21 2011-01-26 贝希尔治疗学股份有限公司 Methods and immune modulatory nucleic acid compositions for preventing and treating disease
CN100546998C (en) 2002-12-23 2009-10-07 戴纳伐克斯技术股份有限公司 Immunostimulatory sequence oligonucleotides and using method
JP2005055812A (en) 2003-08-07 2005-03-03 Olympus Corp Projector device and desk having the projector device fitted therein
US20070009899A1 (en) 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
ES2385657T3 (en) 2004-09-01 2012-07-27 Dynavax Technologies Corporation Methods and compositions for the inhibition of innate immune responses and autoimmunity
AU2005316503A1 (en) 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
CN101379195B (en) * 2005-12-20 2012-05-09 艾德拉药物股份有限公司 Immunostimulatory activity of palindromic immune modulatory oligonucleotides (IMO tm) contiaining different lengths of palindromic segments
MX2008012993A (en) * 2006-04-07 2008-12-18 Idera Pharmaceuticals Inc Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8.
EP1881080A1 (en) 2006-07-18 2008-01-23 Institut Gustave Roussy Toll like receptor 4 dysfunction and the biological applications thereof
AU2008317261B2 (en) 2007-10-26 2015-04-09 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
CN103153346A (en) * 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 Methods of treatment using tlr7 and/or tlr9 inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
WO2001068697A2 (en) * 2000-03-17 2001-09-20 Gorczynski Reginald M Methods and compositions for immunoregulation
WO2003085110A2 (en) * 2002-04-05 2003-10-16 Santaris Pharma A/S Oligomeric compounds for the modulation hif-1alpha expression
WO2005086835A2 (en) * 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
WO2007095387A2 (en) * 2006-02-17 2007-08-23 Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COOK P D: "MAKING DRUGS OUT OF OLIGONUCLEOTIDES: A BRIEF REVIEW AND PERSPECTIVE", NUCLEOSIDES & NUCLEOTIDES, MARCEL DEKKER, INC, US, vol. 18, no. 6/07, 1 June 1999 (1999-06-01), pages 1141 - 1162, XP008049860, ISSN: 0732-8311 *
JARVIS T C; ET AL: "OPTIMIZING THE CELL EFFICACY OF SYNTHETIC RIBOZYMES. SITE SELECTIONAND CHEMICAL MODIFICATIONS OF RIBOZYMES TARGETING THE PROTO-ONCOGENE C-MYB", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 271, no. 46, 15 November 1996 (1996-11-15), pages 29107 - 29112, XP002042583, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
EP2209896A2 (en) 2010-07-28
US8962579B2 (en) 2015-02-24
US20110003885A1 (en) 2011-01-06
AU2008317261B2 (en) 2015-04-09
EP2361980A1 (en) 2011-08-31
US20150275216A1 (en) 2015-10-01
EP2361980B1 (en) 2016-12-07
WO2009055076A2 (en) 2009-04-30
JP5749492B2 (en) 2015-07-15
CA2703931C (en) 2016-08-16
AU2008317261A1 (en) 2009-04-30
EP2209896B1 (en) 2017-03-01
CA2703931A1 (en) 2009-04-30
JP2011500084A (en) 2011-01-06
US9476053B2 (en) 2016-10-25

Similar Documents

Publication Publication Date Title
WO2009055076A3 (en) Methods and compositions for inhibition of immune responses and autoimmunity
WO2007109812A3 (en) Immunopotentiating compounds
HK1211463A1 (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
WO2006031878A3 (en) Imidazoquinoline compounds
AP2965A (en) Therapeutic compositions and the use thereof
RS20070305A (en) Formulations in the form of foam as modificators of immune response foamlike formulations as immunity modificators
WO2008037380A3 (en) Alkyl benzoate mixtures
GT200900049A (en) DERIVATIVES OF 2-ARIL-6-FENIL-IMIDAZO [1,2-A] PIRIDINAS, ITS PREPARATION AND THERAPEUTIC APPLICATION
WO2009056550A3 (en) Bupropion hydrobromide and therapeutic applications
ZA200800206B (en) "One-way valve for medical infusion lines and the like"
ZA201000468B (en) Therapeutic compositions and the use thereof
WO2008116078A3 (en) Stimulation of an immune response by cationic lipids
WO2009027820A3 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
WO2009089494A3 (en) Pharmaceutical compositions
WO2009059048A3 (en) (+)-opioids and methods of use
EP2152304A4 (en) Nanoemulsion therapeutic compositions and methods of using the same
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
WO2009114810A3 (en) Use of ellagitannins as inhibitors of bacterial quorum sensing
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2008089201A3 (en) Heterocyclic-substituted piperidine as orl-1 ligands
EP2045253A4 (en) alpha-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
WO2009019294A3 (en) Bupropion hydrobromide and therapeutic applications
WO2007075923A3 (en) Treatment of synucleinopathies
AU2008303948A8 (en) Use of the peptide Asn-Asp-Asp-Cys-Glu- Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu alone or in combination with the peptide Thr-Thr-Ser-Gln-Val- Arg-Pro-Arg as a therapeutic agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08841867

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008317261

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2703931

Country of ref document: CA

Ref document number: 2010531068

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2008841867

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008841867

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008317261

Country of ref document: AU

Date of ref document: 20081027

Kind code of ref document: A